circ-Magi1 Blood Detection for Early Cerebral Stroke Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for cerebral stroke, such as CT and MRI, have limitations in early detection and can be harmful or costly, and there is a lack of effective blood-based indicators for accurate diagnosis.
Innovation Solution
Utilizing circular RNA-circ-Magi1 as a biomarker, with detection kits and systems for analyzing its expression levels in blood samples to diagnose or predict cerebral stroke, including reagents, primers, and quantitative PCR methods.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CT examination is used for early stroke diagnosis, then diagnostic capability is improved, but radiation harm increases and diagnostic accuracy within 24 hours remains insufficient
Solution Approach 1:
The patent introduces circular RNA-circ-Magi1 as an intermediary biomarker that mediates between the need for accurate stroke diagnosis and the avoidance of harmful radiation. This biomarker can be detected through blood tests, providing diagnostic information without requiring harmful imaging procedures, thus resolving the contradiction between diagnostic capability and radiation harm.
Solution Approach 2:
The patent replaces the mechanical/imaging-based CT system with a biochemical detection system based on circular RNA analysis. This substitution eliminates radiation exposure while maintaining diagnostic capability through molecular biomarker detection in blood samples.
2Measurement precision
If MRI is used to compensate for CT defects in early stroke diagnosis, then diagnostic accuracy is improved, but device accessibility worsens due to contraindications and cost
Solution Approach 1:
The patent uses circular RNA-circ-Magi1 as an intermediary biomarker that can be universally detected through blood tests regardless of patient contraindications. This approach bypasses the accessibility limitations of MRI (pacemakers, metal implants, cost) while maintaining high diagnostic accuracy through specific biomarker detection.
Solution Approach 2:
The patent employs a simple, inexpensive blood test approach using circular RNA detection instead of expensive MRI equipment. The biomarker detection can be performed with basic laboratory equipment, making it accessible and affordable for widespread use.
3Ease of operation
If conventional blood tests are used for stroke diagnosis, then simplicity is maintained, but diagnostic effectiveness is insufficient
Solution Approach 1:
The patent changes the parameter being measured in blood tests from conventional markers to circular RNA-circ-Magi1, a specific molecular biomarker that is highly effective for stroke diagnosis. This parameter change maintains the simplicity of blood collection while dramatically improving diagnostic effectiveness through specific and sensitive biomarker detection.
Solution Approach 2:
The patent applies local quality by focusing on a specific, highly relevant biomarker (circular RNA-circ-Magi1) rather than using broad conventional blood tests. This targeted approach concentrates diagnostic power on the most informative parameter, improving effectiveness while maintaining operational simplicity.
Data Source
AI summary
Provided is an application of a circular RNA in the preparation of a cerebral stroke diagnosis product, belonging to the field of circular RNA medical treatments. Provided is a kit, comprising a reagent and/or test paper and/or gene chip for detecting a circular RNA-circ-Magi1. The nucleotide sequence of the circular RNA-circ-Magi1 is as shown in SEQ ID NO: 1 or SEQ ID NO: 4. Further provided is the application of a detection system for the diagnosis, assisted diagnosis or prognosis evaluation of cerebral stroke, and a detection reagent of the circular RNA-circ-Magi1 in the preparation of a kit, test paper, chip or high-throughput sequencing platform for the diagnosis, assisted diagnosis or prognosis evaluation of cerebral stroke.